Custom Pharma Services (CPS) as a strategic business unit of Dr Reddy’s draws on years of knowledge and expertise in pharmaceutical development and manufacturing to provide innovators with customised services and solutions for intermediates, active ingredients and finished dosages. Within a short span, we have become one of the largest pharmaceutical outsourcing players from India and a global partner-of-choice. We have a track record of bringing innovations to the market quickly, efficiently and economically with the capability to supply both small-scale clinical trial quantities and commercial-scale requirements. Our end-to-end services make a compelling value proposition to our global innovator customers.
No data available
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.. EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:. •
Lilly is developing a growing portfolio of best in class pharmaceutical products by applying the latest research from our own laboratories and from collaborations with eminent scientific organisations worldwide. In 2003 the company's world-wide sales were more than $12 billion. Lilly employs more than 43000 people worlwide and markets medicines in 158 countries. Lilly Research Laboratories (the R&D division of the company) employs more than 8000 people from a wide variety of disciplines. The company has R&D facilities in 9 countries and currently conducts clinical trials in more then 60 countries around the world. . . Lilly's internal research efforts are focused in the following major therapeutic areas: cancer, cardiovascular diseases, endocrinology, neuroscience, gene regulation, bone biology, immunomodulation and Inflammation Compounds in late stage development, and those currently being launched have promise to address the needs of patients with sepsis, cancer, diabetes, depression, osteoporosis, erectile dysfunction, urinary incontinence and attention deficit hyperactivity disorder.. . In pursuit of innovation Lilly seeks to incorporate those cutting edge technologies which support the high quality, rapid identification and investigation of novel compounds.. . The company approach to innovation includes a commitment to the philosophy of research without walls - a stated commitment to partnership and external collaboration. Currently Lilly Research Laboratories has more than 120 active collaborations with external scientists.
Watch our Member Showcase video here https://bit.ly/3HZGpJI
Emberion develops and produces graphene photonics and electronics that will revolutionise infrared photodetectors and thermal sensors in applications ranging from hyperspectral and thermal imaging to night vision and X-ray detection.
The mission of EMBL-EBI is to: provide freely available data and bioinformatics services to all facets of the scientific community in ways that promote scientific progress; contribute to the advancement of biology through basic investigator-driven research in bioinformatics; provide advanced bioinformatics training to scientists at all levels; and help disseminate cutting-edge technologies to industry. . The research and service activities of EMBL-EBI span the entire spectrum of life science and remain at the cutting edge of the computational sciences. All our major data resources are the products of international collaborations. We work with other data providers to ensure that our data repositories, and those of our collaborators, are comprehensive and up to date. We also actively participate in international efforts to develop data standards.. . The EMBL-EBI Industry Programme engages our industrial users with the latest bioinformatics research, service development, standards activities, pre-competitive opportunities and training https://www.ebi.ac.uk/industry.
Empyrean Therapeutics is focused on developing next generation off-the-shelf cell therapies to enable global and affordable cures for cancer and rare disease. We are building unique technologies, cellular assets and engineering processes which combine to deliver a powerful platform for rapidly manufacturing cellular drugs with novel disease fighting properties. . . Headquartered at the Babraham Research Campus, south of Cambridge, and working with leading clinical partners and academic experts, we are combining world class skills in gene editing with expertise in stem cell programming and precise genetic control to unlock the true potential of designer cellular medicines.
Strategic and finance advisory
Immunotherapeutics company targeting a new class of tumour specific antigens